Patients with recurrent platinum-sensitive EOC with no more than 2 prior courses of chemotherapy were randomized to single-agent sorafenib 400 mg twice daily or combination sorafenib 400 mg bid ( days 2-19 ) with IV carboplatin ( AUC 6 ) and IV paclitaxel 175 mg/m ( 2 ) ( S+C / T ) every 3 weeks .